Institute for Rare Diseases in Hematology
- A. Univ. Prof. Dr. Paul Knöbl
Facharzt f. Innere Medizin, Hämato-Onkologie und Internistische Intensivmedizin
Oberarzt an der Medizinischen Universität Wien
Klinik f. Innere Med. 1, Abt. Hämatologie u. Hämostaseologie
Work at the Institute
The Karl-Landsteiner Institute for Rare Diseases in Hematology was founded in 2019 for studies on rare and complex blood disorders and other hematological problems.
The head of the Institute, Prof.Dr.Paul Knoebl, a senior physician at the Medical University of Vienna, Austria, has experience with such disorders since many years.
Thrombotic microangiopathies (TMA) are serious, life-threatening syndromes of different etiologies, associated with hemolysis, thrombocytopenia and severe organ dysfunction. The thrombotic-thrombocytopenic purpura (TTP) is currently investigated in several research projects. One major aim is to establish a national registry to include the characteristics of patients with TMA.
Another rare disease is the acquired hemophilia A (AHA), an autoimmune disease characterized by severe bleeding. The treatment of this disease is complex and expensive, therefore dedicated expertise is needed to handle such patients. Therefore, a national registry should be established to cover the characteristics of all patients with AHA.
Other potential projects are in development:
- coagulopathy in the critically ill patients
- new therapeutic possibilities for patients with bleeding disorders
- changes in the microbioma of patients with hematological diseases
The Karl-Landsteiner Institute for Rare Diseases in Hematology is closely collaborating with the Medical University of Vienna, especially with the Departments of Medicine 1, Clinical Pharmacology, Emergency Medicine, Laboratory Diagnosis, and Transfusion Medicine. International collaborations exist with the Society on Thrombosis and Hemostasis (GTH), the Inselhospital Bern, the Medizinische Hochschule Hannover and the pharmaceutical industry.